GlassScriptPhysician profile
Amanda B Baden
NPI 1790810505
$2,749.13
in general payments reported to CMS, 2019-2025
12 companies · $956 in 2025
The $956 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $186 · 2022: $223 · 2023: $472 · 2024: $748 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $754.33 | 2023-2025 | Infuse, Vyzulta, Biotrue |
| Alcon Vision LLC | $580.57 | 2020-2025 | Hydrus Microstent, Precision7, Total30 |
| Sun Pharmaceutical Industries INC. | $423.02 | 2022-2025 | Cequa |
| Coopervision INC. | $261.93 | 2019-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.79 | 2019-2020 | |
| Dompe US, INC. | $142.38 | 2024 | Oxervate |
| Amgen INC. | $124.46 | 2024 | Tepezza |
| Abbvie INC. | $103.66 | 2024-2025 | |
| Rxsight INC | $64.67 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Glaukos Corporation | $51.17 | 2022-2025 | Istent Infinite, Idosetr |
| Harrow Eye, LLC | $51.05 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $22.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Baden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.